SmartCella Holding AB
Anastasiya Karaivanova is a Manufacturing Engineer at Procella Therapeutics AB, contributing to the technical transfer of the company's first product to Clinical Phase I GMP production since June 2022. Responsibilities include ensuring cleanroom GMP certification and compliance. Formerly part of Procella Therapeutics' R&D team as a Research Associate, Anastasiya conducted QC analysis utilizing Flow Cytometry to support production and product development efforts. Prior experience includes a role as a Master Thesis Student at SciLifeLab and as a Technical Support Engineer at Rock Valley College, where responsibility involved CANVAS support. Anastasiya holds a Master's degree in Microbiology from Stockholm University, a Bachelor of Science in Molecular Biology from West Virginia Wesleyan College, and an Associate of Science in Biology from Rock Valley College.
This person is not in any teams
SmartCella Holding AB
SmartCella, founded in 2014, is an innovative biotechnology company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and gene therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and Procella. Smartwise is developing and manufacturing a first-in-class endovascular delivery device, the Extroducer, that enables direct tissue/organ infusions through the vessel wall directly into to hard-to-reach organs and tumors. There is a significant unmet need in the field of targeted delivery of different types of therapies for regeneration of tissue and for treatment of cancer tumors. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively out-licensing the technology to global companies with therapies that benefit from direct delivery. SmartCella Solutions create novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments. A pipeline of projects within regeneration and tolerization, focusing on oncology, is in pre-clinical development. Procella has advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing of cell based therapies, with a proven platform to take stem cell projects from discovery phase to clinical development. A globally licensed cardiac stem cell therapy is entering clinical stages (in collaboration with AstraZeneca) and there is a growing pipeline of projects in different stages of development, with dopamine producing cells for Parkinson´s Disease and our own iMSCs most advanced.